# Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT02864381** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 144 (actual)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Andecaliximab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02864381
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-01
- **Primary completion:** 2017-11-08
- **Final completion:** 2019-08-23
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2020-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02864381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02864381, "Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02864381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*